(株)免疫生物研究所の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|---|---|---|
東証GRT | 医薬品 | 4570/E00986 | Immuno-Biological Laboratories Co.,Ltd. |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|---|---|---|---|---|---|---|---|---|
2016/03/18 | 日証協 | 204,640株 | +0.2% | 2,100株 | -4.55% | 281,597株 | +0.21% | 1,100株 | -73.81% |
2016/03/11 | 日証協 | 204,240株 | -2.85% | 2,200株 | 0% | 280,997株 | -0.68% | 4,200株 | -65.85% |
2016/03/04 | 日証協 | 210,240株 | +4.21% | 0株 | -100% | 282,907株 | +8.68% | 12,300株 | +1117.82% |
2016/02/26 | 日証協 | 201,740株 | -8.15% | 10,000株 | -35.9% | 260,307株 | -7.1% | 1,010株 | -94.9% |
2016/02/19 | 日証協 | 219,640株 | +3.19% | 15,600株 | +239.13% | 280,197株 | -0.25% | 19,800株 | +97.49% |
2016/02/12 | 日証協 | 212,840株 | +0.38% | 4,600株 | +84% | 280,897株 | +1.78% | 10,026株 | +122.8% |
2016/02/05 | 日証協 | 212,040株 | +3.67% | 2,500株 | +66.67% | 275,971株 | +8.32% | 4,500株 | -46.43% |
2016/01/29 | 日証協 | 204,540株 | -12.3% | 1,500株 | -87.9% | 254,771株 | -6.91% | 8,400株 | -6.67% |
2016/01/22 | 日証協 | 233,240株 | +0.86% | 12,400株 | +65.33% | 273,671株 | -3.49% | 9,000株 | +18.42% |
2016/01/15 | 日証協 | 231,240株 | +1.67% | 7,500株 | 0% | 283,571株 | +0.42% | 7,600株 | +280% |
2016/01/08 | 日証協 | 227,440株 | -0.66% | 0株 | 0% | 282,371株 | +3.14% | 2,000株 | -28.57% |
2015/12/30 | 日証協 | 228,940株 | 0% | 0株 | 0% | 273,771株 | -0.33% | 2,800株 | +3.7% |
2015/12/25 | 日証協 | 228,940株 | -7.4% | 0株 | 0% | 274,671株 | -4.52% | 2,700株 | -37.21% |
2015/12/18 | 日証協 | 247,240株 | -1.51% | 0株 | -100% | 287,671株 | +0.7% | 4,300株 | -68.15% |
2015/12/11 | 日証協 | 251,040株 | -0.95% | 9,300株 | -41.14% | 285,671株 | +1.46% | 13,500株 | +2600% |
2015/12/04 | 日証協 | 253,440株 | -26.99% | 15,800株 | +276.19% | 281,571株 | -22.04% | 500株 | -99.14% |
2015/11/27 | 日証協 | 347,140株 | -16.14% | 4,200株 | +162.5% | 361,171株 | -4.44% | 58,400株 | +2654.72% |
2015/11/20 | 日証協 | 413,940株 | +22.2% | 1,600株 | -89.81% | 377,971株 | +31.44% | 2,120株 | -86.41% |
2015/11/13 | 日証協 | 338,740株 | -15.43% | 15,700株 | -78.04% | 287,551株 | -19.58% | 15,600株 | +116.67% |
※株式分割は考慮していませんのでご注意ください。